Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
NEW YORK, Oct. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
The Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies.
The report provides a detailed understand and analysis of how and why companies enter option and evaluation deals. The majority of deals are multicomponent whereby the licensor offers a right to option and evaluation the resultant product of the research collaboration. There are also numerous pure option and evaluation deals whereby the products originator takes on a partner in order to maximize a products presence in the marketplace.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all option and evaluation deals announced since 2009 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual option and evaluation contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of option and evaluation dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in option and evaluation as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of option and evaluation deals. The chapter includes numerous case studies to enable understanding of both pure option and evaluation deals and multicomponent deals where option and evaluation forms a part.
Chapter 4 provides a review of the leading option and evaluation deals since 2009. Deals are listed by headline value, signed by bigpharma and biobiotech, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of option and evaluation deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of option and evaluation deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 7 provides a comprehensive and detailed review of option and evaluation deals signed and announced since 2009 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the option and evaluation deal.
In addition the report includes a series of appendices containing a comprehensive listing of all option and evaluation deals announced since 2009.
Each listing is organized as an appendix by company A-Z, stage of development at signing, and therapeutic area. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous tables and figures that illustrate the trends and activities in option and evaluation dealmaking since 2009.
In conclusion, this report provides everything a prospective dealmaker needs to know about option and evaluation alliances.
Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics provides the reader with the following key benefits:
• In-depth understanding of option and evaluation deal trends since 2009
• Analysis of the structure of option and evaluation agreements with numerous real life case studies
• Comprehensive access to over 900 actual option and evaluation deals entered into by the world's biopharma companies
• Detailed access to actual option and evaluation contracts enter into by the leading fifty bigpharma companies
• Insight into the terms included in a option and evaluation agreement, together with real world clause examples
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnsotics is intended to provide the reader with an in-depth understanding of the option and evaluation trends and structure of deals entered into by leading biopharma companies worldwide.
Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnsotics includes:
• Trends in option and evaluation dealmaking in the biopharma industry since 2009
• Analysis of option and evaluation deal structure
• Case studies of real-life option and evaluation deals
• Access to over 900option and evaluation deal records
• The leading option and evaluation deals by value since 2009
• Most active option and evaluation dealmakers since 2009
• The leading option and evaluation partnering resources
In Option and Evaluation Partnering Terms and Agreements n Pharma, Biotech and Diagnsotics , the available deals are listed by:
• Company A-Z
• Headline value
• Stage of development at signing
• Therapeutic area
• Technology type
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
Chapter 1 – Introduction
Chapter 2 – Trends in option and evaluation dealmaking
2.2. Difference between option and evaluation deals
2.2.1. Types of option agreement
2.3. Trends in option and evaluation deals since 2009
2.4. Option-based deals
2.4.1. Attributes of option-based deals
2.4.2. Reasons for entering an option-based deal
2.4.3. Uptake of option exercise
2.4.4.The future of option-based deals
2.5. Co-promotion options
2.5.1. Attributes of co-promotion in multi-component deals
2.5.2. Reasons for including co-promotion options in a deal
2.5.3. Uptake of co-promotion rights
2.5.4. Co-promotion rights as bargaining chips
2.5.5. The future of co-promotion as part of multicomponent deals
2.6. Company acquisition options
2.6.1. Case study 1: Cephalon – Ception – January 2009
2.6.2. Case study 2: Endo – Indevus – January 2009
2.6.3. The future of option to acquire deals
Chapter 3 – Overview of option and evaluation deal structure
3.2. Option and evaluation agreement structure
3.2. Example evaluation agreements
3.2.1.a. Case study 3: BioGenerix – Neose
3.3. Option agreement structure
3.3.1. Example option agreements
3.3.1.a. Option to license
Case study 4: Biogen Idec – Isis Pharmaceuticals – June 2012
3.3.1.b. Option to extend/expand applications/territories
Case study 5: Novartis –Prometheus
3.3.1.c. Option to finance
Case study 6: Archemix– Merck KGaA
3.3.1.d. Option to co-promote
Case study 7: Teva – OncoGenex Pharmaceuticals
3.3.1.e. Option to manufacture/supply
Case study 8: NPS Allelix – Nycomed
3.4. Option to acquire agreement structure
3.4.1. Example acquisition option clauses
3.4.1.a. Case study 9: MGI Pharma – AkaRx
3.4.1.b. Case study 10: Abbott – Ibis Biosciences – Isis Pharmaceuticals
Chapter 4 – Leading option and evaluation deals
4.2. Top option and evaluation deals by value
4.3. Most active option and evaluation dealmakers
4.4. Big pharma option and evaluation deal activity
4.5. Big biotech option and evaluation deal activity
Chapter 5 – Big pharma option and evaluation deals
5.2. How to use option and evaluation deals
5.3. Bigpharma company option and evaluation deal profiles
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Chapter 6 – Bigbiotech option and evaluation deals
6.2. How to use bigbiotech partnering deals
6.3. Bigbiotech option and evaluation partnering company profiles
Swedish Orphan Biovitrum
The Medicines Company
Chapter 7 – Option and evaluation contracts directory
7.2. Company A-Z
7.3. By stage of development
7.4. By therapeutic target
Central Nervous System
7.5. By technology type
About Wildwood Ventures
Recent report titles from CurrentPartnering
Order Form – Reports
Appendix 1 – Company A-Z
Appendix 2 – By therapy area
Appendix 3 – By stage of development at signing
Appendix 4 – By technology type
Appendix 5 – Option and evaluation dealmaking references
Appendix 6 – Resources
Appendix 7 – Deal type definitions
Appendix 8 – Example option and evaluation contract document
About Wildwood Ventures
Recent report titles from CurrentPartnering
Order Form – Reports
Order Form – Reports
TABLE OF FIGURES
Figure 1: Definition of option and evaluation deals
Figure 2: Types of option right
Figure 3: Trends in option and evaluation deal announcements, 2009-2013
Figure 4: Recent option-based deals
Figure 5: Example deals where co-promotion options have been actively exercised, since 2000
Figure 6: Recent 'option to acquire' deals
Figure 7: Components of the option and evaluation deal structure
Figure 8: Types of option in an agreement
Figure 9: Attributes of option terms:
Figure 10: Top option and evaluation deals by value since 2009
Figure 11: Most active option and evaluation dealmakers 2009-2013
Figure 12: Bigpharma – top 50 – option and evlaution deals 2009 to 2013
Figure 13: Bigpharma option and evaluation deal frequency - 2009 to 2013
Figure 14: Big biotech – top 50 – option and evlaution deals 2009 to 2013
Figure 15: Big biotech option and evaluation deal frequency - 2009 to 2013
To order this report: Option and Evaluation Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Contact Clare: firstname.lastname@example.org
Intl: +1 339-368-6001
©2012 PR Newswire. All Rights Reserved.
WWBT-TV NBC 12
P.O. Box 12
On Your Side
Video and Pics